Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® ▼ (abemaciclib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
How to manage haematologic toxicities with Verzenios® (abemaciclib) in early breast cancer
Dose modification is recommended for patients who develop Grade 3 or Grade 4 haematologic toxicities. Grade 1 or Grade 2 neutropenia does not require dose modification.
Management recommendations for haematologic toxicities with abemaciclib
Please find
- dose modification and management recommendations in Dose modification and management recommendations for haematologic toxicities
- Common Terminology Criteria for Adverse Events (CTCAE) Grade definitions for haematologic toxicities in NCI CTCAE Grade Definitions